Zobrazeno 1 - 10
of 51
pro vyhledávání: '"M V, Relling"'
Autor:
William E. Evans, Sima Jeha, Steven W. Paugh, C H Pui, Mignon L. Loh, Elixabet Lopez-Lopez, Seth E. Karol, Naomi J. Winick, Elizabeth A. Raetz, Robert J Autry, Christian A. Fernandez, Jun J. Yang, Meenakshi Devidas, Xueyuan Cao, Stephen P. Hunger, C. Cheng, Joseph R. McCorkle, Eric C. Larsen, William L. Carroll, Barthelemy Diouf, Wenjian Yang, Laura B. Ramsey, M. V. Relling
Publikováno v:
Leukemia
Leukemia, vol 31, iss 6
Leukemia, vol 31, iss 6
The causes of individual relapses in children with acute lymphoblastic leukemia (ALL) remain incompletely understood. We evaluated the contribution of germline genetic factors to relapse in 2225 children treated on Children's Oncology Group trial AAL
Autor:
Ching-Hon Pui, M. V. Relling, Christian A. Fernandez, Colton Smith, Fred D. Finkelman, Laura B. Ramsey, Seth E. Karol, Chengcheng Liu, William E. Evans, Sima Jeha
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 352(3)
A murine model was developed that recapitulates key features of clinical hypersensitivity to Escherichia coli asparaginase. Sensitized mice developed high levels of anti-asparaginase IgG antibodies and had immediate hypersensitivity reactions to aspa
Autor:
John T. Sandlund, C H Pui, M. V. Relling, Deqing Pei, Hak Lj, Jeffrey E. Rubnitz, Bo Wang, Cheng Cheng
Publikováno v:
Leukemia. 18:1072-1077
Polyethylene glycol-conjugated (PEG) asparaginase is approved for use in patients who develop allergy to other forms of asparaginase, although its ability to deplete asparagine systemically in patients with hypersensitivity has not been well elucidat
Autor:
S C, Kaste, A, Qi, K, Smith, H, Surprise, E, Lovorn, J, Boyett, R J, Ferry, M V, Relling, S A, Shurtleff, C H, Pui, L, Carbone, M M, Hudson, K K, Ness
Publikováno v:
Pediatric bloodcancer. 61(5)
We sought to improve lumbar spine bone mineral density (LS-BMD) in long-term survivors of childhood acute lymphoblastic leukemia (ALL) using calcium and cholecalciferol supplementation.This double-blind, placebo-controlled trial randomized 275 partic
Autor:
T. W. Synold, Eric Masson, William E. Evans, Ching-Hon Pui, John T. Sandlund, M. V. Relling, John D. Schuetz, Qing Liu
Publikováno v:
Journal of Clinical Investigation. 97:73-80
Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL) and is commonly given in high doses. However, the rationale for high-dose MTX (HDMTX) has been challenged recently. To determine
Autor:
Ching-Hon Pui, Barthelemy Diouf, Deqing Pei, Gabriele Stocco, Maria Grazia Valsecchi, M. V. Relling, Jones Terreia, Steven W. Paugh, Cheng Cheng, Laura B. Ramsey, Kristine R. Crews, Margherita Londero, Wenjian Yang, William E. Thierfelder, Giuliana Decorti, William E. Evans, Marco Rabusin, Joseph R. McCorkle, Raffaella Franca
Publikováno v:
Human molecular genetics. 21(21)
Treatment-related toxicity can be life-threatening and is the primary cause of interruption or discontinuation of chemotherapy for acute lymphoblastic leukemia (ALL), leading to an increased risk of relapse. Mercaptopurine is an essential component o
Autor:
Gaston K. Rivera, Ching-Hon Pui, M. V. Relling, John T. Sandlund, James M. Boyett, Hazem Mahmoud, T. W. Synold, W M Crist, William E. Evans
Publikováno v:
Journal of Clinical Investigation. 94:1996-2001
High-dose methotrexate (HDMTX) is a component of most treatment protocols for childhood acute lymphoblastic leukemia (ALL), yet recent studies of receptor-mediated transport and saturable polyglutamylation have questioned its rationale. To investigat
Autor:
Dan M. Roden, Scott T. Weiss, Rachel F. Tyndale, David A. Flockhart, Alan R. Shuldiner, Kelan G. Tantisira, Daniel F. Hayes, M E Dolan, Ronald M. Krauss, Liewei Wang, Issam Zineh, Richard M. Weinshilboum, Neal L. Benowitz, M. V. Relling, Teri E. Klein, Claire M. Brett, Catherine Schaefer, Kathleen M. Giacomini, Victor I. Reus, Deanna L. Kroetz, Howard L. McLeod, Anne T. Nguyen, Mark J. Ratain, Julie A. Johnson, Todd C. Skaar, Russ B. Altman
Publikováno v:
Clinical pharmacology and therapeutics. 81(3)
The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to correlate drug response with genetic variation. Several research groups concentrate on drugs use
Autor:
C. H. Pui, W. Yang, Soma Das, Y. Lin, Steven A. Wrighton, L. Fan, Cynthia Brimer, J. Y. Guo, Michael D. Amylon, Bruce M. Camitta, Mahfoud Assem, Ann K. Daly, Javier G. Blanco, J. Zhang, S. C. Lee, Jatinder K. Lamba, S. Kishi, L. Z. Wang, Erin G. Schuetz, A. B. Ong, Naomi J. Winick, Kenneth E. Thummel, Peter M. Kuehl, Patrick Maurel, Thierry Dervieux, R. Lim, Frederick G. Behm, M. V. Relling, B. C. Goh, John D. Schuetz, Mark S. Boguski, Edwin H. Cook, Gary L. Rosner, Stephen C. Strom, P. Chen, Paul B. Watkins, H. L. Lim, Michael L. Hancock, Stephen D. Hall, Robert O. Bash, Raman Venkataramanan, Kazuto Yasuda, Mathew J. Edick, H. S. Lee, Susana C. Raimondi
Publikováno v:
Scopus-Elsevier
Category: Genotype PharmGKB Submission Numbers: PS113737, PS115406, PS114503, PS200420, PS201057, PS115245 Date of Submission: May 19, 2003 Project: Pharmacogenetics of Anticancer Agents, St. Jude Children's Research Hospital HGNC Symbol
Publikováno v:
Annals of hematology. 83
The current cure rate of 80% in childhood acute lymphoblastic leukemia (ALL) attests to the effectiveness of risk-directed therapy developed through well-designed clinical trials. The ongoing Total Therapy Study XV at St. Jude Children's Research Hos